Angiodynamics Stock Price, News & Analysis

AngioDynamics (NASDAQ: ANGO) has announced the enrollment of its first patient in the AMBITION BTK clinical trial, investigating the effectiveness of their Auryon Atherectomy System combined with balloon angioplasty for treating Critical Limb Ischemia (CLI).

The trial will be a multicenter, randomized controlled study involving up to 224 patients across 30 sites, with a parallel registry enrolling up to 1,500 additional patients. The study aims to evaluate freedom from major amputation, freedom from clinically driven target lesion revascularization, and primary patency at 12 months.

The Auryon laser system has already treated over 100,000 patients worldwide and can address all infrainguinal lesion types. This trial is particularly significant as CLI affects a large patient population, with untreated cases facing a 20-25% risk of limb loss within one year.

AngioDynamics (NASDAQ: ANGO) announced the publication of its PRESERVE study results in European Urology, evaluating the NanoKnife System for prostate tissue ablation. The study, involving 121 patients across 17 clinical sites, demonstrated significant success in treating intermediate-risk prostate cancer.

Key findings include 84% of patients remaining free from clinically significant disease at 12 months post-procedure. The study showed remarkable quality-of-life preservation, with 96% maintaining urinary continence and 84% preserving sexual function. The NanoKnife System, which received FDA clearance for prostate tissue ablation in late 2024, uses non-thermal irreversible electroporation (IRE) technology to provide a minimally invasive treatment option.

AngioDynamics (NASDAQ: ANGO) reported strong Q4 and full fiscal year 2025 results, with notable growth in their Med Tech franchise. Q4 highlights include pro forma net sales of $80.2M (up 12.7% YoY), with Med Tech sales reaching $35.8M (up 22.0%) and Med Device sales at $44.4M (up 6.2%).

For FY2025, the company achieved total net sales of $292.7M (up 8.1% YoY), with Med Tech sales growing 19.5% to $126.7M. The company reported positive adjusted EBITDA of $13.1M for the full year and ended with $55.9M in cash. Key achievements include receiving a CPT Category I Code for NanoKnife's IRE treatment and securing a $25M revolving credit facility.

For FY2026, AngioDynamics projects net sales of $305-310M, with Med Tech growth of 12-15% and expects positive free cash flow, despite anticipated tariff impacts of $4-6M.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has scheduled its fiscal 2025 fourth quarter and full-year financial results announcement for Tuesday, July 15, 2025, before market open.

The company will host a conference call at 8:00 am ET on the same day, accessible via phone (1-877-407-0784 domestic, +1-201-689-8560 international) or webcast through the investor relations section of their website. A replay will be available through July 15, 2025, at 11:59 PM ET using passcode 13754203.

AngioDynamics (NASDAQ: ANGO) has announced the enrollment of the first patient in its RECOVER-AV clinical trial, evaluating the AlphaVac F1885 System for treating acute, intermediate-risk pulmonary embolism (PE). This multi-center study follows the system's FDA clearance in April 2024 and CE Mark approval in May 2024. The trial will assess safety, efficacy, and long-term functional outcomes across up to 20 sites in Europe, Canada, and Hong Kong. The study targets a significant medical need, with approximately 435,000 PE events occurring annually in the six largest EU countries. The trial builds on successful results from the U.S. APEX-AV trial, which showed significant improvements in right ventricular function and clot burden reduction. Patients will be monitored for 12 months, with comprehensive assessments including Cardiac MRI and exercise testing.

AngioDynamics (NASDAQ: ANGO) reported its Q3 FY2025 financial results with pro forma net sales of $72.0 million, up 9.2% year-over-year. The company's MedTech segment showed strong performance with $31.3 million in sales, growing 22.2%, while MedDevice sales reached $40.7 million, up 0.9%.

Key highlights include GAAP gross margin of 54.0%, a loss per share of $(0.11), and adjusted EBITDA of $1.3 million. The company received FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation and initiated the AMBITION BTK trial for the Auryon Atherectomy System.

AngioDynamics increased its FY2025 guidance, now expecting net sales of $285-288 million, MedTech sales growth of 14-16%, gross margin of 53-54%, and adjusted EBITDA of $4.0-5.0 million. The company secured a $25.0 million revolving credit line with J.P. Morgan for additional financial flexibility.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has announced a virtual cardiovascular investor event scheduled for Wednesday, April 2, 2025.

The event will commence at 9:00 AM ET, immediately following the company's Fiscal 2025 Third Quarter Financial Results Conference Call at 8:00 AM ET. During this 60-minute session, AngioDynamics will provide an in-depth exploration of their cardiovascular technology portfolio and strategic vision.

Investors can access the webcast through the company's website at www.angiodynamics.com under the 'Investors' section or via the provided registration link.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has announced its upcoming fiscal 2025 third quarter financial results release scheduled for April 2, 2025, before market open.

The company will host two key events on the same day: a financial results conference call at 8:00 AM ET, followed by a virtual cardiovascular investor event at 9:00 AM ET. The latter will provide an in-depth look at the company's cardiovascular technology portfolio and strategic vision.

Investors can participate in the conference call through domestic (1-877-407-0784) or international (+1-201-689-8560) dial-in numbers. Both events will be accessible via webcast through the company's investor relations website. A replay of the call will be available until April 09, 2025, using passcode 13752371.

AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment solutions, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference.

The company's leadership team, including President and CEO Jim Clemmer and EVP/CFO Stephen Trowbridge, will deliver a presentation on Monday, March 17, 2025, at 12:00 p.m. ET. Investors and interested parties can access the live webcast through the 'Investors' section of AngioDynamics' website at www.angiodynamics.com, with a replay option available after the event.